Study On RRM1 Expression Related To Sensitivity Of Non-small-cell Cancer To Gemcitabine In Vitro

Objective:To determine the relation between RRM1 expression and sensitivity of non-small-cell lung cancer to gemcitabin in vitro, providing important theoretical evidence to guide gemcitabine's individual chemotherapy in non-small-cell lung cancer field.Methods:1.44 fresh operative non-small-cell lung cancer samples were collected and immediately used to be tested the sensitivity to gemcitabine with the method of ATP-tumor chemosensitivity assay.2. The expression of RRM1 protein in 44 paraffin-embedded samples of non-small-cell lung cancer were determined through StreptAvidin Peroxidase method.3. Analyzing the relation between RRM1 protein expression and sensitivity of non-small-cell lung cancer to gemcitabine in vitro.Results:1. There were 23(52.3%) cases sensitive to gemcitabine in the 44 fresh non-small-cell lung cancer specimen, and the other 21(47.7%) resistant cases.2. We used S-P method to determine RRM1 protein in 44 paraffin-embedded samples. There were 20 (45.5%) cases with the high levels of RRMl protein, and still another 24(54.5%) cases with the low levels of RRM1 protein.3. Combined with gemcitabine in vitro results, we can learned that there were 17 (70.8%)cases with sensitive to gemcitabine in the high levels of RRM1 protein group,and 6(30.0%) sensitive cases in the low levels of RRM1 protein group. RRM1 high expression group was obviously lower than the low expression group to sensitivity gemcitabine (P<0.05).Conclusions:1. RRM1 high expression of non-small-cell lung cancer was obviously lower than the low expression group to sensitivity gemcitabine.2. RRM1 expression may be useful prognostic factor of non-small-cell lung cancer's chemotherapy with gemcitabine.